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Abstract
Iron–sulfur (Fe-S) clusters are essential for mitochondrial metabo-
lism, but their regulation in pulmonary hypertension (PH) remains
enigmatic. We demonstrate that alterations of the miR-210-ISCU1/2
axis cause Fe-S deficiencies in vivo and promote PH. In pulmonary
vascular cells and particularly endothelium, hypoxic induction of
miR-210 and repression of the miR-210 targets ISCU1/2 down-
regulated Fe-S levels. In mouse and human vascular and endo-
thelial tissue affected by PH, miR-210 was elevated accompanied
by decreased ISCU1/2 and Fe-S integrity. In mice, miR-210
repressed ISCU1/2 and promoted PH. Mice deficient in miR-210,
via genetic/pharmacologic means or via an endothelial-specific
manner, displayed increased ISCU1/2 and were resistant to
Fe-S-dependent pathophenotypes and PH. Similar to hypoxia or
miR-210 overexpression, ISCU1/2 knockdown also promoted PH.
Finally, cardiopulmonary exercise testing of a woman with
homozygous ISCU mutations revealed exercise-induced pulmonary
vascular dysfunction. Thus, driven by acquired (hypoxia) or
genetic causes, the miR-210-ISCU1/2 regulatory axis is a patho-
genic lynchpin causing Fe-S deficiency and PH. These findings
carry broad translational implications for defining the metabolic
origins of PH and potentially other metabolic diseases sharing
similar underpinnings.
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Introduction
Iron–sulfur (Fe-S) clusters ([4Fe-4S] and [2Fe-2S]) are critical bio-
inorganic prosthetic groups that are essential for electron transport
and consequent metabolic processes (Beinert et al, 1997). The
formation of Fe-S clusters is controlled by a conserved set of assem-
bly and scaffold proteins. Current knowledge regarding the impor-
tance of these proteins in human disease has been derived largely
through investigation of genetic mutations (as reviewed by Rouault,
2012). Yet, stemming from the relatively rare occurrence of these
genetic mutations and technical obstacles to measuring these pros-
thetic groups in mammals, the regulation and actions of Fe-S clus-
ters in the wide spectrum of human metabolic disease have been
poorly investigated.
Pulmonary hypertension (PH) is a deadly and increasingly preva-
lent vascular disease where Fe-S biology may figure prominently.
PH is defined by increased pulmonary arterial pressure and lung
vasculopathy, triggered by varied and often disparate stimuli
(Schermuly et al, 2011). Among these triggers, hypoxia and the
actions of its master transcription factors of hypoxia, HIF-1a and
HIF-2a, are well-recognized insults in multiple PH subtypes, includ-
ing pulmonary arterial hypertension (PAH, WHO Group 1) (Bonnet
et al, 2006; Fijalkowska et al, 2010; Farha et al, 2011; Marsboom
et al, 2012) as well as PH associated with hypoxic lung diseases
(WHO Group 3) (as reviewed by Tuder et al, 2013). The pulmonary
vascular response to hypoxia and HIF factors in PH is incompletely
characterized but increasingly has been linked to chronic repression
of mitochondrial metabolism (Cottrill & Chan, 2013). Some factors
have been identified to modulate metabolic processes in the
diseased pulmonary vasculature, but the entire complement of
regulators remains undefined.
Studying cultured cells, we previously reported that hypoxia up-
regulated the HIF-a-dependent microRNA-210 (miR-210), leading to
specific mitochondrial and metabolic alterations (Chan et al, 2009).
In hypoxia, this microRNA (miRNA) decreased expression of its
targets ISCU1 and ISCU2 (iron–sulfur cluster assembly proteins 1/2
or typically described by the single term, ISCU1/2). In mammalian
cells, two splice isoforms of ISCU exist and both serve as scaffolding
proteins essential for the biogenesis of Fe-S clusters. Both transcripts
carry an identical 30 UTR, but they differ in their location: ISCU1 is
located in the cytosol, whereas ISCU2 is located in the mitochondria
(Tong & Rouault, 2000). We found that down-regulation of ISCU1/2
decreased Fe-S-dependent mitochondrial respiration and promoted a
metabolic shift toward glycolysis for energy production. In the acute
setting, this adaptive metabolic shift improved cell survival.
However, the effects in health or disease of chronic activation of the
miR-210-ISCU1/2 axis with consequent repression of Fe-S clusters
in vivo are not known. Based on the pathologic consequences of
metabolic dysfunction in other diseases such as cancer, we hypothe-
sized that chronic repression of Fe-S biogenesis directly drives
dysfunction of mitochondrial metabolism, cellular proliferation, and
frank disease. By interrogating that model further in both acquired
injury (e.g. hypoxia) and genetic human disease (ISCU mut/mut),
we now define the miR-210-ISCU1/2 regulatory axis as a crucial
pathogenic lynchpin of pulmonary vascular disease in vivo.
Results
The miR-210-ISCU1/2 regulatory axis is activated in PH related to
hypoxia and HIF activity
Based on our prior studies of the regulation of miR-210 in pulmonary
arterial endothelial cells (PAECs) (Chan et al, 2009) and the up-regu-
lation of both HIF-1a and HIF-2a in vascular endothelial cells in
hypoxia-relevant PH in mice (Supplementary Fig S1), we hypothe-
sized that the miR-210-ISCU1/2 axis is active in various forms of PH
stemming from hypoxia-dependent or HIF-dependent activity. By
RT–PCR, we found that miR-210 was induced in the lungs of mice
deficient in the von Hippel–Lindau gene (VHL/), a genetic model
of PH driven by constitutive HIF-a activation (Fig 1A, Supplemen-
tary Fig S2A). miR-210 was also up-regulated in lungs of mice
suffering from PH stemming from chronic hypoxia (10% O2)
(Supplementary Fig S2B) and in mouse lungs with more severe PH
(Supplementary Fig S2A) stemming from chronic hypoxia accompa-
nied by serial administration of the VEGF-receptor antagonist
▸Figure 1. The miR-210-ISCU1/2 regulatory axis is activated in endothelium and remodeled vessels in PH.A RT–qPCR reveals that miR-210 was increased in lungs of mice with PH triggered by various conditions: VHL/ as compared with VHL+/+ mice (N = 4/group),
***P < 0.0001 (first graph); hypoxia + SU5416 (Hyp + SU5416) (N = 6/group) as compared with normoxia + SU5416 (Norm + SU5416) (N = 7/group), **P = 0.0015
(second graph); Il6 transgenic versus littermate control mice (N = 4/group), **P = 0.0097 (third graph); and S. mansoni-infected mice (N = 4) compared with non-
infected control mice (N = 5), ***P < 0.0001 (fourth graph).
B From animal subjects in (A), in situ hybridization (ISH, purple stain) revealed increased miR-210 in < 100-lm pulmonary vessels of mice suffering from PH,
*P = 0.0493 for first graph, **P = 0.0015 for second graph, *P = 0.0391 for third graph.
C Representative ISH stain of miR-210 in < 100 lm pulmonary vessels of mice (bottom micrographs) exposed to Hyp + SU5416 compared with Norm + SU5416
(a-smooth muscle actin stain from serial sections, top row of micrographs).
D Increased miR-210 in < 200-lm remodeled pulmonary vessels of patients suffering from PAH (N = 19, Supplementary Table S1) as compared with non-PAH donor
control lung (N = 10). Serial staining with hematoxylin and eosin is displayed in the top row of micrographs; quantification of miRNA ISH, right graph, *P = 0.0167.
E Increased levels of miR-210 in plasma drawn from the pulmonary circulation (pulmonary capillary wedge position, PCWP) of patients with elevated mean
pulmonary arterial pressures (mean PAP ≥ 25 mmHg) compared with control subjects (mPAP < 25 mmHg, N = 5/group, demographics in Supplementary Table S2),
*P = 0.0357.
F, G From animals in (C) and humans in (D), immunohistochemistry (IHC) revealed that the miR-210 targets ISCU1/2 were reciprocally down-regulated in miR-210-
enriched remodeled pulmonary vessels—namely in PH mice exposed to Hyp + SU5416 (F, ***P = 0.0002) and in human PAH patients (G, ***P = 0.0008).
H, I miR-210 expression (H) was increased (***P = 0.0003), and ISCU1/2 expression (I) was decreased (***P < 0.0001) in PECAM+ pulmonary vascular endothelial cells
isolated from PH mice (Hyp + SU5416) as compared with control (Norm + SU5416) (N = 4/group, left bars).
Data information: In (A, B), mean expression of miR-210 in control groups was assigned a fold change of 1, to which all samples were compared. Error bars reflect SEM.
Mouse tissue scale bar: 50 lm, human tissue scale bar: 100 lm.
EMBO Molecular Medicine Vol 7 | No 6 | 2015 ª 2015 The Authors
EMBO Molecular Medicine Iron–sulfur deficiency in pulmonary hypertension Kevin White et al
696
ANorm + SU5416
Mouse
Non-PAH PAHC
egnahc dlof 012-
Ri
m
0
5
10
15
20
25 ***
Norm + SU5416
Hyp + SU5416
0
1
2
3
4
5 *
<25mmHg
>25mmHg
Va
sc
ul
ar
 IS
C
U
1/
2 
le
ve
ls
IH
C
 (a
rb
itr
ar
y 
un
its
)
0
5
10
15
20 ***
Non-PAH
PAH
slevel 2/ 1
U
CSI r al ucsaV
) sti nu yr arti br a( 
C
HI
F
ISCU1/2
N
on
-P
A
H
P
A
H
D
E
Human
0
1
2
3
4
Norm + SU5416
Hyp + SU5416
**
m
iR
-2
10
 fo
ld
 c
ha
ng
e
0
5
10
15
WT
VHL-/-
***
 m
iR
-2
10
 fo
ld
 c
ha
ng
e
0
5
10
15
20
WT
IL6 Tg
**
m
iR
-2
10
 fo
ld
 c
ha
ng
e
0
1
2
3
4
5
WT
IL6 Tg
Va
sc
ul
ar
 m
iR
-2
10
 le
ve
ls
 
IS
H
(a
rb
itr
ar
y 
un
its
)
0
1
2
3
Norm + SU5416
Hyp + SU5416
Va
sc
ul
ar
 m
iR
-2
10
 le
ve
ls
IS
H
(a
rb
itr
ar
y 
un
its
)
0
0.5
1.0
1.5
2.0
WT
VHL-/-
Va
sc
ul
ar
 m
iR
-2
10
 le
ve
ls
IS
H
(a
rb
itr
ar
y 
un
its
)
B
*** *
*
Non-PAH
PAH
Va
sc
ul
ar
 m
iR
-2
10
 le
ve
ls
IS
H
 (a
rb
itr
ar
y 
un
its
)
miR-210 expression (whole lung) Vascular miR-210 expression (ISH)
H
Norm + SU5416
Hyp + SU5416
I
0
1
2
3egnahc dl of 012-
Ri
m
Norm + SU5416  ISCU
Hyp + SU5416 ISCU
0
200
400
600
U
CSI fo eul av nae
m ehT
 ecnecser oulf 
*** ***
Norm + SU5416
Hyp + SU5416
ISCU1/2
N
or
m
+ 
SU
54
16
H
yp
+ 
SU
54
16
Lung (mouse)Lung (mouse) Lung (mouse) Lung (mouse)Lung (mouse) Lung (mouse)
H
 &
 E
m
iR
-2
10
Plasma 
PECAM+ cells PECAM+ cellsPECAM+ cells
C
ou
nt
s
Fluorescence (Red)
m
iR
-2
10
α
-S
M
A
G
Hyp + SU5416
0
1
2
3
 m
iR
-2
10
 fo
ld
 c
ha
ng
e
Lung (mouse)
***
WT
S. Mansoni 
4
1
2
3
0
α-SMA
Figure 1.
ª 2015 The Authors EMBO Molecular Medicine Vol 7 | No 6 | 2015
Kevin White et al Iron–sulfur deficiency in pulmonary hypertension EMBO Molecular Medicine
697
SU5416 (Fig 1A). Corresponding with the link between inflamma-
tory cytokine stimulation and up-regulated HIF activity, miR-210
was also induced in inflammatory mouse models of PH driven by
transgenic pulmonary interleukin-6 (IL-6) expression [elevated right
ventricular systolic pressures reported in Steiner et al (2009)] and by
chronic S. mansoni infection (Fig 1A, Supplementary Fig S2A). In
correlation, in situ miRNA staining was performed using specific
mouse models where reliable histologic assessment of pulmonary
vascular cell types was possible. Such staining revealed that miR-
210 expression was induced within the diseased pulmonary vascula-
ture of mice (< 100 lm external diameter vessels) (Fig 1B and C), as
compared with non-diseased tissue and miR-scrambled control
probe (Supplementary Fig S3A). Induction of miR-210 was
observed in remodeled pulmonary vessels (Fig 1B) but not in other
peripheral vascular tissue (Supplementary Fig S4A). MiR-210
expression was also up-regulated in the small diseased pulmonary
arterioles (< 200 lm external diameter) in human PAH lung tissues
compared with those arterioles observed in non-diseased human
lung tissue (Fig 1D; patient demographics in Supplementary Table
S1). Among other vascular cell types, staining for miR-210 was
also evident in the intimal layer of remodeled vessels, consistent
with prior studies implicating the robust actions of miR-210 in
PAECs (Chan et al, 2009). Circulating, extracellular miR-210 was
also significantly elevated in plasma sampled adjacent to the
pulmonary vascular space (pulmonary capillary wedge position,
PCWP) from PH individuals (mean pulmonary arterial pressures,
mPAP ≥ 25 mmHg, PCWP ≤ 15 mmHg) as compared with PH-free
individuals (mPAP < 25 mmHg, Fig 1E, demographic information
in Supplementary Table S2). Such findings are consistent with a
growing literature reporting that diseased tissues, which express
increased levels of specific miRNAs, can release those miRNAs into
the extracellular space and into the circulating plasma (Creemers
et al, 2012). Conversely, the direct miR-210 targets ISCU1/2,
detected specifically by immunohistochemical stain (Supplementary
Fig S3B), were down-regulated in diseased pulmonary vasculature
of mice and humans (Fig 1F and G) suffering from PH, but not in
unaffected peripheral vasculature (Supplementary Fig S4B–D).
Guided by the intimal expression of miR-210, we wanted to
quantify specifically the expression of miR-210 and ISCU1/2
in diseased pulmonary vascular endothelial cells. To do so, a
MACS-based cellular sorting system was used to purify PECAM-
positive (PECAM+) pulmonary vascular endothelial cells from PH
mice exposed to hypoxia + SU5416 or hypoxia alone. These
PECAM+ cells (> 95% purity, Supplementary Fig S5) displayed an
up-regulation of miR-210 by RT–PCR (Fig 1H, Supplementary
Fig S6A) and a down-regulation of ISCU1/2 (by antibody staining
and flow cytometry, Fig 1I, Supplementary Fig S6B). In contrast,
the expression of other reported targets of miR-210, such as SDHD,
COX10, E2F3, and Ephrin A3, was unchanged or even increased in
diseased PECAM+ cells from hypoxic mice as assessed by flow
cytometry (Supplementary Fig S6C–F) or immunohistochemical
stain of remodeled pulmonary vessels (Supplementary Fig S7A and B).
Such findings emphasize the unique importance of ISCU1/2 as a
canonical miR-210 target gene in this context. Furthermore, taken
together, we can conclude that, in both mouse models and human
examples of PH in vivo, the miR-210-ISCU1/2 regulatory axis is
activated in small diseased pulmonary vessels, particularly in endo-
thelial cells.
Fe-S integrity is decreased in hypoxic pulmonary vascular cells
and in hypoxic PH in vivo
Previously, we postulated that the down-regulation of Fe-S levels in
PAECs is directly mediated by miR-210 and ISCU1/2 (Chan et al,
2009). To establish this principle, we optimized a previously vali-
dated fluorescent detection system of intracellular [2Fe-2S] clusters
(Hoff et al, 2009). Specifically, this system utilizes two fusion
proteins: one carrying the N-terminal half of the Venus fluorescent
protein fused to the glutaredoxin 2 (GRX2) protein and another
carrying the Venus C-terminal half fused to GRX2. When expressed
in the same cell, these fusion constructs only fluoresce after GRX2
homodimerization—a process quantitatively dependent upon intact
[2Fe-2S] clusters. After lentiviral delivery of sensor genes to cultured
human PAECs, mean fluorescence was measured by flow cytometry
of live cells, and sensor expression was quantified by immunoblot.
GCN4 control sensors—fusion proteins that homodimerize indepen-
dent of Fe-S levels—induced consistent sensor expression and fluo-
rescence in all conditions (Fig 2A–C). Similarly, GRX2 sensor
▸Figure 2. Impaired Fe-S cluster integrity in diseased pulmonary vasculature is driven by the miR-210-ISCU1/2 axis.A After lentiviral delivery of GCN4 or GRX2 sensor genes to human PAECs, cellular fluorescence was measured by flow cytometry. Unlike control GCN4 sensors that
homodimerized independent of Fe-S levels and induced consistent fluorescence, fluorescence derived from the GRX2 Fe-S-dependent sensors decreased in hypoxia, as
displayed in representative flow cytometric plots (left) and by quantification of percentage of positive cells [(cell number in M2 gate)/(total cell number) × 100].
Immunoblotting revealed consistent expression of either GRX2 or GCN4 sensors (FLAG-tagged) in hypoxia (Hyp) compared with normoxia (Norm) (N = 3,
***P < 0.0001 for GRX2; N = 3, NS P = 0.1848 for GCN4).
B In contrast to consistent fluorescence from control GCN4 sensors, Fe-S-dependent GRX2 sensor fluorescence was decreased by siRNA knockdown of ISCU1/2 (siISCU)
as compared with control (siCont) (N = 3, ***P < 0.0001 for GRX2; N = 3, NS P = 0.1790 for GCN4).
C GRX2, but not GCN4, sensor fluorescence was decreased after transfection of miR-210 oligonucleotide mimic (miR-210) as compared with control (miRC) (N = 3,
***P = 0.0002 for GRX2; N = 3, NS P = 0.0913 for GCN4). During hypoxic exposure, GRX2, but not GCN4, sensor fluorescence was increased after transfection of an
antisense miR-210 inhibitor (AS210) as compared with control (ASC) (N = 3, **P = 0.003 for GRX2; N = 3, NS P = 0.1194 for GCN4).
D After lentiviral delivery of sensor genes, Fe-S-dependent GRX2 sensor fluorescence was decreased in PECAM-positive cells from PH mouse lung (Hyp + SU5416) as
compared with control non-PH mouse lung (Norm + SU5416, N = 3, ***P < 0.001).
E By electron paramagnetic resonance (EPR) spectroscopy (representative VHL/ versus control lung), Fe-S cluster signal was decreased (left graph) in VHL/ mice
lung tissue (VHL/, N = 3) as compared with WT control lung tissues (WT, N = 5), ***P = 0.0003.
F By EPR, Fe-S-specific signal was decreased (right graph) in human PH-diseased lung tissue harvested at lung transplantation (PH, N = 3, Supplementary Table S3)
compared with non-PH control donor lung tissues (control, N = 3), *P = 0.048.
Data information: In (A–C), sensor expression was confirmed by immunoblot for FLAG epitopes. Error bars reflect SEM.
Source data are available online for this figure.
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expression was consistent among relevant comparisons. Yet, fluo-
rescence derived from the GRX2 sensors decreased in hypoxia
(Fig 2A), reflecting a down-regulation of Fe-S levels. Supporting the
role of the miR-210-ISCU1/2 axis in such Fe-S down-regulation,
Fe-S-dependent GRX2 sensor fluorescence was also decreased in the
absence of hypoxia by small interfering RNA (siRNA) knockdown
of ISCU1/2 (Fig 2B, efficiency of knockdown as demonstrated in
Supplementary Fig S8A) or separately, by forced miR-210 expres-
sion [Fig 2C, expression as we previously reported (Chan et al,
2009)]. Demonstrating the essential role of miR-210 in this hypoxic
response, antisense inhibition of miR-210 partially rescued GRX2
fluorescence in the presence of hypoxia (Fig 2C). Importantly, the
miR-210-ISCU1/2 axis similarly regulated Fe-S levels in endothelial
cells derived throughout the pulmonary vascular tree (Supplemen-
tary Fig S9). Such alterations of Fe-S levels were also not dependent
upon reduction of total mitochondrial content in cultured pulmo-
nary vascular cell types exposed to hypoxia (Supplementary Fig
S10A and B), in mice exposed to hypoxia + SU5416 (Supplementary
Fig S10C), or in mice where miR-210/ISCU1/2 were directly manip-
ulated (Supplementary Fig S10D and E). Moreover, changes in Fe-S
expression were also not dependent on total pulmonary iron
content (Supplementary Fig S10F). Therefore, activation of miR-210
and down-regulation of ISCU1/2 are sufficient for repressing Fe-S
levels in endothelial cells throughout the human pulmonary
vascular tree and are necessary to do so during hypoxia.
To determine whether Fe-S cluster biogenesis is repressed in PH
in vivo, Fe-S-dependent GRX2 sensors as well as electron paramag-
netic resonance (EPR) spectroscopy were utilized to quantitatively
analyze Fe-S cluster levels in PH-diseased lung tissue. First, in
PECAM+ cells derived from PH mice exposed to hypoxia + SU5416,
a down-regulation of Fe-S-specific fluorescent signal was observed
after lentiviral transduction of GRX2 sensors but not with GCN5
control sensors (Fig 2D). In corroboration, as demonstrated by
the alteration in EPR peak-to-peak spectroscopic signal lungs from
VHL/ mice, Fe-S cluster levels were significantly down-regulated
in PH-diseased VHL/ lung as compared with non-diseased
littermate VHL+/+ control lung (Fig 2E). Finally, Fe-S cluster levels
were decreased in human lung tissue derived from PH patients
undergoing lung transplantation (N = 3, patient demographics in
Supplementary Table S3) as compared with donor tissue derived
from non-PH persons (N = 3) (Fig 2F). Taken together, these data
demonstrate that deficiencies in Fe-S integrity, mediated in large
part by hypoxia and the miR-210-ISCU1/2 axis, are prevalent in PH
and may play a fundamental role in controlling pulmonary vascular
homeostasis and disease.
Hypoxic induction of miR-210 induces oxidative stress and
pulmonary vascular proliferation via repression of Fe-S
biogenesis and mitochondrial metabolism
To delineate the metabolic actions of miR-210 in vivo (Fig 3A), we
analyzed mice carrying homozygous deletions of the mmu-miR-210
gene (miR-210/) as described (Prosser et al, 2011; Mok et al,
2013). Despite absent expression of miR-210 (Supplementary
Fig S11), mice were viable at baseline and displayed no grossly
abnormal phenotype. However, in contrast to decreased ISCU1/2 in
diseased pulmonary vessels of WT mice exposed to
hypoxia + SU5416, miR-210/ mice displayed preserved ISCU1/2
expression in small pulmonary vessels (< 100 lm) under those same
conditions (Fig 3B). Consistent with the role for ISCU1/2 and Fe-S
biogenesis in mitochondrial electron transport in cultured cells (Chan
et al, 2009), mitochondrial respiratory complex activity (Complex I)
was also preserved in pulmonary tissue harvested from miR-210/
mice as compared with decreased activity in diseased WT mice
exposed to hypoxia + SU5416 (Fig 3C). Correspondingly, despite
increased pulmonary vascular expression of the HIF-responsive
glucose transporter-1 (GLUT1) in diseased WT mice (Fig 3D), GLUT1
in miR-210/ pulmonary vessels was unchanged. Thus, by delineat-
ing a consistent reliance on mitochondrial metabolism in miR-210/
mice even under PH disease conditions, these findings demonstrated
that miR-210 is necessary, at least in part, for the metabolic dysregu-
lation observed in diseased pulmonary vasculature in vivo.
▸Figure 3. miR-210 regulates Fe-S biogenesis, mitochondrial function, and downstream PH pathways in vivo and is necessary to induce hypoxic PH in mice.A Schema of comparing miR-210/ and WT mice after hypoxia + SU5416 (PH) versus normoxia + SU5416 (control).
B By immunohistochemistry (IHC), ISCU1/2 was unchanged in < 100 lm pulmonary vessels of miR-210/ mice exposed to Hyp + SU5416 (N = 6) versus
Norm + SU5416 (N = 7), NS P = 0.2833.
C Fe-S-dependent Complex I-specific activity was decreased in WT PH mice as compared with control (N = 7/group, left bars, ***P < 0.0001), but activity was
preserved in the lungs of miR-210/ mice in either condition (N = 8/group, right bars), NS P = 0.3693.
D IHC demonstrated that pulmonary vascular GLUT1 was increased in WT PH mice (left bars, ***P = 0.0006), but GLUT1 was unchanged in miR-210/ mice in
either condition (right bars, NS P = 0.9967).
E 3-nitrotyrosine (3-NT) was increased in pulmonary vessels of WT PH mice but was reduced in miR-210/ mice in either condition (N = 6/group) (***P < 0.0001,
NS P = 0.4087).
F In PH conditions, endothelin-1 was decreased in miR-210/ lung tissue compared with WT tissue (N = 5/group), **P = 0.007.
G PCNA was increased in WT PH pulmonary vessels but was decreased in miR-210/ tissue exposed to either condition (N = 5/group) (**P = 0.0096, *P = 0.0124,
*P = 0.0263 for miR-210/).
H PCNA was increased in PECAM+ endothelial cells from PH versus non-PH mice (N = 3/group, **P = 0.0052).
I Unlike WT mice (black bars) demonstrating increased right ventricular systolic pressure (RVSP) after Hyp + SU5416 (N = 10) versus Norm + SU5416 (N = 11),
hemodynamic dysregulation was significantly alleviated in miR-210/ mice (white bars, N = 11) (***P < 0.0001, *P = 0.0258, **P = 0.0059).
J Compared with WT controls (N = 9), miR-210/ mice (N = 8) displayed a blunted increase of the Fulton index (RV/LV + S) under PH versus baseline conditions
(expressed as a ratio of RV/LV + S under Hyp + SU5416 versus Norm + SU5416, *P = 0.031).
K–M Under PH (black bars, N = 8/group) versus baseline conditions (white bars, N = 6/group), pulmonary vascular remodeling was alleviated in miR-210/ mice, as
visualized via histology (L), and confirmed by decreased % arteriolar muscularization (K, **P = 0.001, **P = 0.0045 for miR-210/, *P = 0.0158) and decreased
vessel wall thickness (M, ***P < 0.0001, **P = 0.0086).
Data information: Error bars reflect SEM. Mouse tissue scale bar: 50 lm.
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Next, we wanted to determine whether this miR-210-dependent
metabolic shift is associated with phenotypes consistent with the
cellular manifestations of PH. Expression levels of 3-nitrotyrosine, a
marker of oxidative stress in the pulmonary vasculature, were
significantly reduced in the pulmonary vessels of miR-210/ mice
as compared with WT controls following hypoxia + SU5416
(Fig 3E). Under the same conditions, expression of the potent vaso-
constrictor endothelin-1 was also decreased in miR-210/ pulmo-
nary tissue (Fig 3F), consistent with alterations of endothelin-1 in
cultured PAECs by miR-210 (Supplementary Fig S12). Finally,
actively proliferating PCNA-positive pulmonary vascular cells were
increased in WT controls exposed to hypoxia + SU5416, as quanti-
fied by immunofluorescent microscopy (Fig 3G). Consistent with
the activation of the miR-210-ISCU1/2 axis in vascular endothelial
cells, based on flow cytometric analysis, such PCNA up-regulation
corresponded specifically to PECAM+ pulmonary vascular endo-
thelial cells (Fig 3H). In contrast, PCNA expression was reduced in
the miR-210/ pulmonary vascular wall compared with WT
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controls (Fig 3G). Thus, we conclude that chronic induction of miR-
210 in vivo represses ISCU1/2 as a primary target, leading to disrup-
tion of Fe-S biogenesis, mitochondrial metabolism, and pathologic
alteration of the proliferative and oxidative states of the pulmonary
vasculature.
Pulmonary vascular induction of miR-210, particularly in the
endothelium, promotes PH
Given the altered metabolic and cellular phenotypes driven by miR-
210, we wanted to determine whether chronic induction of this
miRNA is necessary and sufficient to promote PH. With
hypoxia + SU5416, miR-210/ mice were substantially protected
against the development of PH, exhibiting only slight increases in
RVSP as compared with more substantial elevations in WT control
mice (Fig 3I). By echocardiography, left ventricular dysfunction was
exonerated as a cause for PH (Supplementary Fig S13A). Yet,
compared with WT controls, miR-210/ mice displayed a blunted
increase of RV/LV + S (Fulton index) under disease versus baseline
conditions, thus indicating at least partial protection from the RV
hypertrophic response and consistent with the hemodynamic
improvement (Fig 3J). Furthermore, distal pulmonary vessel remod-
eling was significantly alleviated in miR-210/ mice compared with
diseased WT littermates (Fig 3K–M). Thus, miR-210 is necessary for
the hypoxic induction of PH in vivo.
To establish more definitively the causative actions of miR-210
and ISCU1/2 in PH, we next employed a variety of protocols for
pharmacologic administration of miR-210 oligonucleotide mimics or
inhibitors as well as a siRNA specific for ISCU1/2 in the pulmonary
vasculature of mice. To do so, the time of hypoxic exposure and
pharmacologic treatments were tailored to each type of condition
and delivery system, in order to minimize any possible confounding
effects of systemic overload of siRNA or miRNA oligonucleotides.
First, in the presence of SU5416 but in the absence of hypoxia,
chronic pulmonary expression of miR-210 in WT mice was achieved
by serial intrapharyngeal injections of liposomally encapsulated
miR-210 oligonucleotide mimics, as adapted from prior protocols
(Bertero et al, 2014) (Fig 4A). Delivery resulted in miR-210 up-
regulation in whole lung tissue (Fig 4B) and in small pulmonary
vessels (Fig 4C) but not the heart or other organs (Supplementary
Fig S14). Such localized pulmonary delivery led to repression of
pulmonary vascular ISCU1/2 (Fig 4D, Supplementary Fig S7E and F).
Interestingly, levels of other reported miR-210 targets such E2F3
and Ephrin A3 (Supplementary Fig S7C and D) were unchanged,
again indicating the importance of ISCU1/2 in the specific actions
of miR-210 in this context. Consistent with findings in cultured
PAECs (Supplementary Fig S12A), endothelin-1 in pulmonary
tissue was also up-regulated by miR-210 (Fig 4E). In turn, chronic
miR-210 expression led to elevated right ventricular systolic
pressure (RVSP) compared with WT littermates treated with
miR-Control (Fig 4F). MiR-210 also induced pulmonary vascular
remodeling, as demonstrated by substantial muscularization and
medial thickening in the distal pulmonary vessels (Fig 4G and H).
Thus, even in the absence of hypoxia, miR-210 induction is
sufficient to induce pulmonary vascular dysfunction in vivo.
Separately, endogenous miR-210 in WT mice was pharmacologi-
cally inhibited by serial weekly intravenous injections of 20-F- and
20-O-methoxyethyl (20MOE)-modified anti-miR-210 oligonucleotides,
as we previously described (Bertero et al, 2014). A regimen to prevent
PH development (“prevention study”; Fig 5A) down-regulated miR-
210 expression in lungs of mice exposed to hypoxia + SU5416, as
assessed by RT–qPCR of whole lung (Fig 5B), by RT–qPCR of
PECAM+ pulmonary vascular cells from diseased lungs (Fig 5C),
and by in situ pulmonary vascular staining (Fig 5D). This decrease
of miR-210 was accompanied by de-repression of ISCU1/2 expres-
sion as assessed by in situ staining (Fig 5E) and flow cytometric
assessment of PECAM+ endothelial cells (Fig 5F). Anti-miR-210
prevented endothelin-1 up-regulation (Supplementary Fig S12B),
and, as in miR-210/ mice, anti-miR-210 also reduced the number
of proliferating PCNA-positive vascular cells (Fig 5H). As a result,
anti-miR-210 prevented RVSP elevation (Fig 5I) and vessel remodel-
ing (Fig 5J and K) as compared with mice exposed to anti-miR-
Control. Similarly, when administered to ameliorate already existing
PH [using a “reversal study” protocol which we previously
described (Bertero et al, 2014)] (Fig 5L), anti-miR-210 similarly
decreased pulmonary vascular miR-210 (Fig 5M), increased ISCU1/2
expression (Fig 5N), and significantly ameliorated elevations of
RVSP and vessel remodeling (Fig 5O–Q).
To ensure that SU5416 was not confounding the actions of anti-
miR-210, mice were exposed to anti-miR-210 and hypoxia alone
with significant prevention of hemodynamic manifestations of PH
(Fig 6A). In that context, to determine whether endothelial-specific
actions of the miR-210-ISCU1/2 axis are necessary for hypoxia-
induced PH development, serial delivery in vivo of anti-miR-210 to
the pulmonary vascular endothelium was achieved using the
recently described 7C1 nanoparticle delivery system (Dahlman et al,
2014). When intravenously administered to ameliorate already
existing PH induced by hypoxia alone without SU5416 (“reversal
study”; Fig 6B), endothelial delivery of 7C1-encapsulated anti-miR-
210 led to a decrease in miR-210 specifically in PECAM+ pulmonary
vascular endothelial cells but not in other PECAM-negative pulmo-
nary cells (Fig 6C). Corresponding with such endothelial-specific
delivery, miR-210 level was decreased and ISCU1/2 expression was
increased in those same PECAM+ cells (Fig 6D and E). Mirroring
the effects of miR-210 in cultured PAECs (Supplementary Fig S12B)
and the effects of systemic delivery of anti-miR-210 (Fig 5G),
endothelin-1 was decreased by anti-miR-210 as compared to control
(Fig 6F). Moreover, such endothelial-specific miR-210 repression
significantly ameliorated elevations of RVSP (Fig 6G) and vessel
remodeling (Fig 6H and I). Thus, using both genetic and pharmaco-
logic methods, we conclude that chronic induction of endogenous
miR-210, particularly in endothelial cells, is necessary and sufficient
to promote hypoxia-induced PH in vivo.
Knockdown of ISCU1/2 independent of miR-210 in the pulmonary
vasculature promotes PH
To demonstrate definitively the importance of ISCU1/2 and Fe-S
biogenesis in the actions of miR-210 and hypoxia in PH, we assessed
the consequences of repressing ISCU1/2 in the pulmonary vascula-
ture independent of hypoxia or miR-210 manipulation. To do so, we
utilized the Staramine-mPEG nanocomplex intravenous system to
intravenously deliver siRNAs directly to the pulmonary vasculature
of mice in vivo (Polach et al, 2012) (Fig 7A). First, delivery of
siISCU did not alter miR-210 expression either under normoxia or
hypoxia compared to the siControl mice (Fig 7B and C). Compared
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to control siRNA-treated littermate mice (siCont), mice that were
administered a siRNA targeting murine ISCU1/2 (siISCU, efficiency
of knockdown in cultured MEFs as shown in Supplementary
Fig S8B) exhibited a reduction of ISCU1/2 in the pulmonary vascula-
ture (Fig 7D), a consequent decrease in EPR-measured Fe-S integrity
(Fig 7E) without a reduction in total mitochondrial DNA content
(Supplementary Fig S9D), and an up-regulation of endothelin-1
expression (Fig 7F). As a result, in the presence of either normoxia +
SU5416 or hypoxia + SU5416 (days 7–21), ISCU1/2 knockdown
resulted in RVSP elevation (Fig 7G) as well as increased vessel
remodeling (Fig 7H and I) as compared with siCont-treated litter-
mate controls. Again, left ventricular dysfunction was exonerated as
a cause for PH (Supplementary Fig S13B). Thus, similar to both
hypoxia and forced miR-210 expression, knockdown of ISCU1/2
promoted PH, thereby confirming the direct importance of Fe-S
biogenesis in pulmonary vascular homeostasis and PH manifesta-
tion in vivo.
Exercise-induced pulmonary vascular dysfunction in an individual
genetically deficient for ISCU
Beyond hypoxic activation of miR-210, other triggers, independent
of hypoxia and HIF, may reduce ISCU1/2 and thus provoke pulmo-
nary vascular dysfunction. Exceptionally rare homozygous intronic
ISCU mutations in humans exist, causing defective ISCU transcript
splicing and accompanied by profound, but not complete, deficiency
in ISCU activity (Rouault & Tong, 2008). Such persons are plagued
by a mitochondrial myopathy and lactic acidosis. Importantly, such
persons also suffer from extreme exertional dyspnea which has
never been fully explained by myopathy alone (Linderholm et al,
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1969; Heinicke et al, 2011) but is consistent with exercise-induced
pulmonary vascular dysfunction (so-called exercise-induced PAH’)
(Tolle et al, 2008b). Guided by our cellular and rodent findings
above, we sought to determine whether persons genetically deficient
in ISCU exhibit manifestations of PH either at rest or with exercise.
A 29-year-old woman with known homozygous intronic ISCU
mutations was recruited for study (Sanaker et al, 2010). At rest,
echocardiography revealed normal right ventricular function and
size, while pulmonary arterial catheterization revealed normal right
and left heart filling pressure but with a mean pulmonary arterial
pressure at the upper limits of normal [mPAP = 21 mmHg; normal
< 20.6 mmHg (Badesch et al, 2009)]. Advanced cardiopulmonary
exercise testing revealed exertional dyspnea with a markedly
depressed VO2max (495 ml/min, 25% of predicted) that was driven
largely by impaired systemic oxygen extraction [Ca-vO2max =
4.4 m/dl (33% of predicted)], corresponding with her known
mitochondrial myopathy. There was no pulmonary mechanical limit
(VEmax/MVV = 28%), but there was mixed lactic acidemia (2.7–
7.2 mM, rest to peak exercise) and respiratory alkalemia at peak
exercise (PaCO2 = 28 mmHg, arterial pH 7.38)—the latter well
described in patients with mitochondrial myopathies (Heinicke
et al, 2011). Importantly, abnormally increased pulmonary vascular
resistance (PVR) during exercise (maximal PVR at exer-
cise = 135 dynes s/cm5, normal < 80 dynes s/cm5 in persons
< 50 years (Groves et al, 1987; Tolle et al, 2008b)] was observed,
accompanied by elevated mean PAP [maximal mPAP = 31 mmHg;
normal < 29 mmHg in persons < 50 years (Badesch et al, 2009)],
together consistent with exercise-induced pulmonary vascular
dysfunction as defined by contemporary diagnostic criteria (Tolle
et al, 2008b). A pulmonary vasculopathy was also endorsed by
increased DPAP/DCO and DTPG/DPCWP ratios (Table 1) (Lewis,
2010), and an elevated VE/VCO2 slope (50.5; normal < 30) was
consistent with a pulmonary vasculopathy (Ting et al, 2001)
coupled with her mitochondrial myopathy and hyperventilation.
Finally, a 4-week treatment with an oral pulmonary vasodilator
[phosphodiesterase 5 (PDE5) inhibitor tadalafil] significantly
increased her functional capacity, as quantified by an improvement
of > 100 m on 6-min walk test (6 MWT, Table 2). Together, these
data comprise the first-known observation of clinically significant
pulmonary vascular disease in individuals genetically deficient in
ISCU1/2, thus carrying implications for clinical care paradigms in
these persons. Moreover, together with our cellular and rodent stud-
ies, these results confirm the direct causative relationship of the
miR-210-ISCU axis with PH, as driven by either acquired (hypoxia
driven) or human genetic (ISCU mut/mut) alterations.
Discussion
We present evidence in mice and humans whereby the miR-210-
ISCU1/2 axis regulates the pulmonary vascular and endothelial
expression of Fe-S clusters both through acquired injury (e.g.
hypoxia) and genetic mutations. As the dynamic functions of Fe-S
clusters in most disease states have not been investigated due to
substantial technical challenges, these findings to our knowledge
constitute the first targeted analysis of these prosthetic groups in
vascular tissue, pulmonary or otherwise. Furthermore, using genetic
and pharmacologic methods to perform gain-of-function and loss-of-
function analyses in the rodent pulmonary vasculature in vivo
coupled with the first-known observation of pulmonary vasculo-
pathy in an ISCU mut/mut human, we define the miR-210-ISCU1/2
axis as an overarching upstream pathogenic mechanism, central to
the vascular and endothelial metabolic alterations that promote PH
(Fig 7J).
These findings emphasize both the importance and novelty of
ISCU1/2 and its regulation of Fe-S cluster integrity critical to pulmo-
nary vascular pathogenesis. Mechanistic plausibility is supported by
case reports linking defects in mitochondrial oxidative phosphoryla-
tion to PH (Barclay et al, 2005) as well as human genetic evidence
associating mutations in the Fe-S biogenesis protein NFU1 with
pulmonary vascular remodeling (Navarro-Sastre et al, 2011). While
other factors have been identified that modulate metabolic altera-
tions in PH (as reviewed by Tuder et al, 2011; Cottrill & Chan,
2013), many of these are canonical protein factors operating
through previously well-explored processes—such as altered
tricarboxylic acid cycle enzyme activity, mitochondrial membrane
◀ Figure 5. Antisense inhibition of miR-210 protects against and improves existing manifestations of PH in vivo.A Schema of the strategy to determine whether antisense inhibition of miR-210 (anti-miR-210) prevents PH secondary to Hyp + SU5416 exposure (“prevention
protocol”).
B–D Intravenous delivery of anti-miR-210 down-regulated miR-210 expression in whole lung tissue (N = 7/group), ***P < 0.0001 (B), the pulmonary vasculature as
assessed by in situ staining (N = 7/group), ***P = 0.0003 (C), and PECAM+ vascular endothelial cells derived from whole lung tissue (N = 4/group), **P = 0.0013
(D).
E Correspondingly, anti-miR-210 delivery resulted in preservation of ISCU1/2 expression in < 100-lm pulmonary vessels as compared to anti-miR-Control (N = 5/
group), **P = 0.0011.
F Similarly, ISCU1/2 expression was preserved in PECAM+ endothelial cells derived from mice treated with anti-miR-210 (N = 4/group), **P = 0.0016.
G Endothelin-1 was decreased in lung tissue from mice treated with anti-miR-210 during Hyp + SU5416 exposure (N = 6/group), *P = 0.0181.
H As assessed by in situ immunofluorescence, PCNA was decreased in pulmonary vessels (< 100 lm) after anti-miR-210 delivery, **P = 0.001.
I–K Anti-miR-210 delivery (N = 10/group) ameliorated the elevation of RVSP, **P = 0.0031 (i) and vascular remodeling, as reflected by increased percent of
muscularized arterioles (N = 8/group, **P = 0.0091) (J) and increased medial thickness relative to vessel diameter in < 100-lm pulmonary vessels (N = 6/group,
**P = 0.0021) (K).
L Schema of the strategy to determine whether anti-miR-210 improves existing PH (“reversal protocol”).
M, N Pharmacologic inhibition of miR-210 (N = 7/group) down-regulated pulmonary expression of miR-210, ***P < 0.0001 (M), and preserved ISCU1/2 expression in
< 100-lm pulmonary vessels, **P = 0.0015 (N).
O–Q In contrast to anti-miR-Control (N = 8), anti-miR-210 ameliorated the elevation of RVSP (N = 10/group, ***P < 0.0001) (O) and pulmonary vascular remodeling
(N = 7/group, **P = 0.0022, *P = 0.0167) (P–Q).
Data information: Error bars reflect SEM. Mouse tissue scale bar: 50 lm.
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potential, or coupling of oxidative phosphorylation to energy
production. In contrast, alteration of mitochondrial respiratory
complexes has been reported primarily after genetic mutation [such
as in cancer (Brandon et al, 2006)] but rarely via a dynamic regula-
tory pathway in acquired mammalian diseases. Our findings offer an
alternative paradigm of pathogenesis whereby mitochondrial respira-
tory activity is dysregulated, independent of respiratory complex
protein expression but critically dependent on miR-210, ISCU1/2,
and Fe-S integrity. Because Fe-S clusters are not represented by the
transcriptome or proteome, it is not surprising that this pathogenic
axis has been missed until now. Therefore, our results not only
provide a mechanistic explanation linking Fe-S biogenesis and
mitochondrial respiratory activity to PH but also establish PH as the
first of perhaps many mammalian “iron–sulfur” diseases driven by
miR-210, ISCU1/2, and deficiencies in Fe-S clusters.
Beyond mitochondrial metabolism, it is also possible that other
Fe-S-dependent mechanisms may contribute to consequent PH
manifestations. For example, Fe-S clusters have been implicated in
chromosomal and telomere homeostasis (Netz et al, 2012; Stehling
et al, 2012), consistent with the association of telomere length and
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E Correspondingly, endothelial-specific anti-miR-210 (N = 6/group) increased ISCU1/2 expression in PECAM+ cells even in the presence of chronic hypoxia,
***P = 0.0003.
F–I Delivery of anti-miR-210 (N = 5/group) decreased endothelin-1 in hypoxic mouse lung tissue, *P = 0.0198 (F). As a result, in contrast to anti-miR-Control (N = 8),
endothelial-specific anti-miR-210 ameliorated the elevation of RVSP (N = 6), **P = 0.0024 (G), and pulmonary vascular remodeling (N = 6/group), **P = 0.0021,
*P = 0.0117 (H–I).
Data information: Error bars reflect SEM. Mouse tissue scale bar: 50 lm.
EMBO Molecular Medicine Vol 7 | No 6 | 2015 ª 2015 The Authors
EMBO Molecular Medicine Iron–sulfur deficiency in pulmonary hypertension Kevin White et al
706
A B D
E G
H a-SMA
mro
N
6145
US
+
py
H
6145
US
+
0Day 21
siISCU vs siCont (40µg)
(start) (end)
ISCU1/2 knockdown
105 15
10% O2 + SU5416 vs 21% O2 + SU5416
Norm + SU5416 Hyp + SU5416
0
5
10
15
20
25
30
35
***
**
**
Norm
+ SU5416
Hyp 
+ SU5416
slevel
2/1
U
CSIralucsaV
)stinu
yrartibra(
C
HI
g
H
m
m
PSV
R
0
5
10
15
20
25
30
35
***
**
Norm
+ SU5416
Hyp
+ SU5416
0
5
10
15
20
25
***
*
noitaziralucsu
m
%
0.0
0.1
0.2
0.3 ***
**:ssenkci ht ll a
wl esseV
r et e
mai dl essev
siCont siISCU1/2
0.0
0.5
1.0
1.5
egnahc
dlof
012-
Ri
m
siCont
siISCU
I
ns ns
24
26
28
30
Em
do
th
el
in
-1
 (p
g/
20
μg
)
Norm
+ SU5416
siCont
siISCU
**
siCont
siISCU
0.0
0.5
1.0
1.5 egnahc
dlof
012-
Ri
m
C
siCont
siISCU
siCont
siISCU
siCont
siISCU
siCont
siISCU
0
50
100
150
dx
"/
dB
*
siISCU
siCont
siCont
siISCU
0
20
40
60
-20
-40
-60
-80
3460 3480 3500 3520 3540 3560
dx
"/
dB
B (Gauss)
Lung (mouse) Lung (mouse)
Lung (mouse)
Lung (mouse) Lung (mouse) Lung (mouse)
F
Norm
+ SU5416
Hyp
+ SU5416
Norm
+ SU5416
Hyp
+ SU5416
Lung (mouse)
Lung (mouse) Lung (mouse) Lung (mouse)
Norm
+ SU5416
Fe-S clusters
Metabolic shift
HIF-α
miR-210
ISCU1/2
 Acquired PH Triggers
(Hypoxia)
Vascular 
proliferation, 
remodeling, &
pulmonary 
hypertension
 Genetic PH Triggers
     (ISCU mut/mut)
? Genetic mutations in 
other Fe-S biogenesis 
genes
? Other causes
(oxidative stress)
? Iron deficiency
? Other hypoxia-dependent
metabolic disorders
(cancer, cardiomyopathies,
neurologic disorders)
J
Figure 7.
ª 2015 The Authors EMBO Molecular Medicine Vol 7 | No 6 | 2015
Kevin White et al Iron–sulfur deficiency in pulmonary hypertension EMBO Molecular Medicine
707
vascular senescence in PH (Noureddine et al, 2011). Alternatively,
in cases of genetic deficiencies of Fe-S biogenesis (Rouault, 2012)
and including deficiencies of ISCU1/2 (Haller et al, 1991; Mochel
et al, 2008), decreases in Fe-S clusters alter cellular iron homeo-
stasis and increase mitochondrial iron deposition. Consistent with
previous descriptions of alternative gene targets of miR-210
important in iron transport (Yoshioka et al, 2012; Qiao et al,
2013), it is possible that miR-210 may exert additional control
over iron homeostasis in vivo. For example, while iron content
in whole-cell lysates of miR-210-expressing PAECs was
unchanged compared with control PAECs (consistent with the
findings of unchanged total pulmonary iron content in hypoxic
mice, Supplementary Fig S10F), mitochondrial iron levels were
greater with miR-210 expression as compared with control
(Supplementary Fig S15). Therefore, given that direct alterations
in iron handling and transport have been identified as a cause
for PH in mice (Ghosh et al, 2013), the complex actions of the
miR-210-ISCU1/2 axis in iron transport may be relevant for PH
pathogenesis even beyond their effects on Fe-S biogenesis and
warrant future investigation.
Upstream of ISCU1/2, our work highlights miR-210 as one of the
several miRNAs known to modulate pulmonary vascular function
and PH in vivo. Similar to the previously reported context-specific
target gene predilection for miR-21 in PH (Parikh et al, 2012), the
apparent favoring of ISCU1/2 as a target of miR-210 in the hypoxic
pulmonary endothelium is not an uncommon scenario in miRNA
biology where, with increased specific miRNA expression, only a
subset of its validated gene targets may display a net down-
regulation. Specific stoichiometry of miRNA to target transcript
levels may dictate the overall effectiveness of target gene down-
regulation (Parikh et al, 2012). Alternatively, indirect regulatory
pathways may exist in hypoxia that ultimately may be more power-
ful stimuli on certain target genes than any direct miR-210 engage-
ment of the target transcripts themselves. Such complex regulation
may serve as homeostatic rheostats. Both possibilities may be active
in this case, resulting in an apparent context-specific predilection for
ISCU1/2 to be subject to net down-regulation. Nonetheless, other
gene targets of miR-210 may still influence PH via processes beyond
mitochondrial function and in cell types other than the pulmonary
endothelium (Chan & Loscalzo, 2010; Gou et al, 2012). Yet, consid-
ering our results demonstrating PH manifestation after repressing
ISCU1/2 alone (Fig 7), we conclude that the actions of miR-210 in
the pulmonary vasculature in large part are concentrated on Fe-S
biogenesis and downstream mitochondrial dysfunction. Comparison
of the roles of miR-210 in different cellular and disease contexts
may further highlight these differences. Additionally, given the
number of potential Fe-S biogenesis targets (Rouault & Tong, 2008;
Figure 7. siRNA knockdown of pulmonary vascular ISCU1/2 in vivo promotes PH.
A Schema of the strategy for pharmacologic inhibition of siRNA knockdown of ISCU1/2 in the pulmonary vasculature of mice in vivo by Staramine-mPEG-mediated
intravenous delivery.
B, C Pharmacologic inhibition of ISCU (N = 8/group) did not influence miR-210 expression in the lungs either after Norm + SU5415, NS P = 0.8634 (B) or
Hyp + SU5416, NS P = 0.9786 (C).
D As compared with control siRNA (siCont) where ISCU1/2 expression was decreased after exposure to Hyp + SU5416 (white bars), pulmonary vascular delivery of
siRNA specific for ISCU1/2 (siISCU) via Staramine-mPEG nanocomplexes (Polach et al, 2012) down-regulated ISCU1/2 in < 100-lm pulmonary vessels in
Norm + SU5416 and Hyp + SU5416 (N = 5/group, ***P = 0.0006, **P = 0.0019 for Hyp + SU5416, **P = 0.0029 for siCont).
E By electron paramagnetic resonance (EPR) spectroscopy (representative siCont versus siISCU lung), Fe-S cluster signal was decreased (quantitative graph, right) in
siISCU mouse lung tissue (N = 4 mice) compared with siCont (N = 5 mice), *P = 0.0143.
F Endothelin-1 was increased in lung tissue after siISCU delivery under normoxic conditions (N = 5/group), **P = 0.0027.
G–I In the absence (left bars) and presence (right bars) of Hyp + SU5416 for 2 weeks, siISCU (black bars) induced elevations in RVSP (***P < 0.0001, **P = 0.0031) (G)
and increased pulmonary vascular remodeling in < 100-lm pulmonary vessels (H, I) as compared with siCont (N = 5/group, ***P = 0.0003, *P = 0.0114 for H;
***P = 0.0006, **P = 0.0098 for I).
J Model of acquired and genetic Fe-S deficiency as a central cause of metabolic dysfunction and PH in mice and humans. Among others, potential translational
implications are highlighted in red text.
Data information: Error bars reflect SEM. Mouse tissue scale bar: 50 lm.
Table 1. Exercise-induced pulmonary vascular dysfunction in an ISCU
mut/mut individual.
Hemodynamic index Rest Peak exercise
RAP (mmHg) 5 12
Mean PAP (mmHg) 21 31
PCWP (mmHg) 7 10
CO (l/min) 6.5 11
PVR (dynes s/cm5) 160 135 (normal < 80 for persons
< 50 years)
DPAP/DCO (mmHg/l/min) 2.2 (normal < 2 for persons
< 50 years)
DTPG/DPCWP 2.3 (normal < 1)
Advanced cardiopulmonary exercise testing was performed on a woman with
homozygous ISCU mutations. At rest, she displayed normal right atrial
pressure (RAP) and pulmonary capillary wedge pressure (PCWP) but a mean
pulmonary arterial pressure (PAP) at the upper limit of normal. During
exercise, RAP and mean PAP were elevated but with PCWP remaining
normal. Most importantly, abnormal indices of pulmonary vascular
resistance (PVR) were evident (including lack of an appropriate decrease in
PVR during exercise and increased ratios of DPAP/DCO and DTPG/DPCWP),
thus fulfilling criteria for “exercise-induced PAH” that do not rely solely upon
changes in mean PAP alone (Tolle et al, 2008b; Lewis, 2010).
Table 2. Improvement of 6-min walk test (6 MWT) in an ISCU mut/mut
individual after initiation of pulmonary vasodilator therapy (PDE5
inhibitor).
Pulmonary vasodilator
6MW distance
(meters)
None 240
Tadalafil (20 mg daily for 7 days
followed by 40 mg daily for 40 days)
360
Tadalafil (20 mg daily for 7 days
followed by 40 mg daily for 166 days)
364
◀
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Rouault, 2012) beyond ISCU1/2, it is plausible that unidentified
miRNAs act in concert with miR-210 to control further Fe-S bio-
genesis and other PH manifestations.
Our findings also emphasize the direct relevance of the miR-
210-ISCU1/2-Fe-S regulatory axis and mitochondrial metabolic
dysfunction in pulmonary arterial endothelial cells for overall PH
development. Previous studies have characterized the metabolic
dysfunction in both PASMCs and cardiomyocytes in the right ventri-
cle in PH but have rarely focused on metabolic dysfunction in endo-
thelial cells (as reviewed in Cottrill & Chan, 2013). Although
mitochondrial oxidative phosphorylation accounts for a minority of
endothelial energy production at baseline, further down-regulation
of such metabolic activity in favor of glycolysis nonetheless has
been observed in diseased PAECs from humans with idiopathic PAH
(Xu et al, 2007), from lambs with PAH secondary to increased
pulmonary blood flow (Sun et al, 2013), and from monocrotaline-
treated rats with PAH (Sun et al, 2014). Yet, this is the first report to
our knowledge that implicates this metabolic dysfunction of endo-
thelial cells as a causative pathogenic event essential to increased
cellular proliferation (Fig 3H), release of endothelin-1 (Figs 3–6),
and overall PH manifestation in vivo (Fig 6). Such results support a
number of existing models of PH where mitochondrial dysregulation
can trigger a pro-proliferative phenotype via modulation of oxida-
tive stress, cellular growth factors, and cellular survival (Cottrill &
Chan, 2013). Indeed, independent of Fe-S biogenesis, a number of
clinical syndromes related to altered mitochondrial respiration
manifest with PH (Sproule et al, 2008; Hung et al, 2012; Rivera
et al, 2013; Catteruccia et al, 2014), thus supporting the direct clini-
cal connection of mitochondrial dysfunction with this disease.
Beyond proliferation, other end-stage phenotypes of PH may also be
directly regulated by mitochondrial function (e.g. vasomotor tone,
thrombosis, vascular stiffening, among others), and future mecha-
nistic studies linking such metabolic dysregulation to such patho-
phenotypes will be crucial for development of improved metabolic
therapies in PH. So, while the miR-210-ISCU1/2 axis indeed appears
active at least to a certain degree in diseased PASMCs (Fig 1C and F,
Supplementary Fig S16), our results demonstrate the particularly
robust actions of miR-210 in PAECs (Chan et al, 2009). Thus, the
elucidation of the miR-210-ISCU1/2-Fe-S axis expands the pervasive
relevance of mitochondrial dysfunction in additional vascular
cell types beyond muscle tissue in PH and emphasizes the therapeu-
tic potential of targeting this metabolic pathway in vascular endo-
thelium.
Stemming from the paucity of human tissue samples derived
during PH development and intrinsic differences of PH among
rodents and humans, more direct evidence of causal pathogenic
mechanisms in pulmonary vascular disease in humans has been
especially difficult to generate. In this case, advanced cardiopulmo-
nary exercise testing successfully unmasked a pathophenotype of
pulmonary vascular dysfunction in a rare ISCU mut/mut individual,
using contemporary criteria of “exercise-induced PAH” and consis-
tent with prior descriptions in other contexts (Kovacs et al, 2009;
Fowler et al, 2011)—with exercise, a blunted fall in PVR to values
> 80 dynes s/cm5 along with mPAP > 30 mmHg in persons
< 50 years (Groves et al, 1987; Tolle et al, 2008b). Notably, the
hemodynamic dysfunction was modest. Nonetheless, this person’s
relatively young age coupled with our ability to make precise inva-
sive hemodynamic measurements allowed us to avoid the pitfalls of
“normal” variations of mPAP and PVR during exercise (Naeije et al,
2013) reported previously by echocardiography (Argiento et al,
2012) and in the elderly (Kovacs et al, 2009, 2012). Thus, the pres-
ence of a primary pulmonary vasculopathy was unambiguous by
these criteria (Tolle et al, 2008b) and was further corroborated by
abnormalities in the pressure–flow relation with exercise, the trans-
pulmonary pressure gradient, and the VE/VCO2 slope in relation to
her age. This finding of pulmonary vascular dysfunction was espe-
cially timely—adding to our rapidly evolving understanding of
exercise-induced pulmonary vascular pathology and in guiding new
clinical care paradigms for this patient population. Specifically, the
patient’s functional improvement on pulmonary vasodilator therapy
with a PDE5 inhibitor suggested a clinical benefit of treating such an
exercise-specific pathophenotype. Notably, as exercise-induced PAH
may increase the risk of more severe PAH in the future (Tolle et al,
2008b), it remains to be seen whether such early clinical treatment
in these individuals could retard the overall development of disease
in these individuals. Finally, in light of advancing evidence of the
causative interplay between impaired limb skeletal muscle oxidative
metabolism and PAH in other populations (Tolle et al, 2008a), it is
an intriguing possibility that mitochondrial dysfunction in both limb
muscle and pulmonary vasculature in this individual may be
responsible for her pulmonary vascular pathophenotype.
In that vein, the concept of miR-210, ISCU1/2, and Fe-S defi-
ciency as pathogenic determinants in PH has even further transla-
tional significance for improving both diagnosis and therapeutic
management of this disease. The finding of increased levels of
plasma-based miR-210 in a small cohort of PH patients (Fig 1E)
could serve as the basis for the future study of miR-210 as a specific
biomarker for PH. Moreover, we have recently shown that extracel-
lular miR-210 can be taken up by recipient tissue to induce ISCU1/2
down-regulation and metabolic effects beyond the source tissue
(Hale et al, 2014). Thus, diseased pulmonary vasculature may even
rely upon circulating miR-210 as a molecular messenger to commu-
nicate with other recipient tissues during disease progression. More-
over, our newly found appreciation for the direct pathogenic
importance of Fe-S deficiency could aid our ability to identify addi-
tional populations suffering from PH or at risk for PH who may
benefit from PH-specific medications. For example, iron deficiency
may affect Fe-S clusters via simple substrate deprivation, thus offer-
ing an explanation for the puzzling clinical association of PH and
iron deficiency (Rhodes et al, 2011; Ruiter et al, 2011; Soon et al,
2011). Alternatively, rare genetic deficiencies in genes other than
ISCU yet critically important in Fe-S biogenesis (e.g. frataxin, ISD11)
may also predispose to PH, perhaps exacerbated in the setting of
hypoxia. Thus, attempts to identify such Fe-S-specific conditions
that predispose to PH development—conditions that otherwise have
been ignored to date—could be especially fruitful.
Our findings also have broad implications on our understanding
of the metabolic origins of PH and may direct us toward more effec-
tive therapeutic targets. The distinct HIF and hypoxia dependence of
miR-210 coupled with the hypoxia-independent genetic (ISCU mut/
mut) predisposition to PH demonstrates the wide spectrum of
human PH subtypes where control of Fe-S integrity controls patho-
genesis, encompassing at least Group 1 PAH (HIF dependent),
Group 3 PH (hypoxia dependent), and likely Group 5 PH (“meta-
bolic” dysfunction) (Simonneau et al, 2013). Future determination
of other PH subtypes that may depend upon Fe-S deficiency could
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also aid in tailoring specific therapies in targeted subtypes based on
Fe-S-dependent metabolic disease origin. To date, no small mole-
cules have been developed that directly control the expression of
Fe-S clusters, but further optimization of a quantitative system for
measurement of Fe-S levels (Fig 2) may hold the key for high-
throughput drug screening. Pharmacologic inhibition of miR-210
(Figs 5 and 6) also could be promising in humans, especially with
the advent of specific anti-miR delivery methods to the pulmonary
vasculature and endothelium (Figs 6 and 7). Finally, this work
could serve as a foundation for discovery of the actions of
miR-210, ISCU1/2, and Fe-S biology in additional diseases beyond
PH that may share similar hypoxic, genetic, and metabolic under-
pinnings.
Materials and Methods
Study design
The study objective was to determine the molecular mechanism
by which Fe-S clusters are repressed in PH and whether such
alterations in Fe-S clusters directly cause metabolic dysregulation
and PH. First, using a fluorescent GRX2 transgene sensor system,
Fe-S clusters were quantified in diseased PECAM+ endothelial
cells from PH mice and in cultured cells in hypoxia or after
manipulation of either miR-210 or ISCU1/2. Fe-S clusters were
independently measured by electron paramagnetic resonance
(EPR) spectroscopy of human lung tissue collected at lung trans-
plantation from non-diseased or PH patients. The number of
patient samples for EPR was limited by clinical availability and
was calculated to measure a 30% difference between the means of
experimental and control groups with a power of 80% and P-value
of 0.01. Diseased pulmonary tissue from mice and separate
cohorts of human patients was subjected to quantitative analysis
by RT–PCR and in situ histology to measure expression of miR-
210 and ISCU1/2. The number of patient samples for histologic
analysis was calculated to measure a 20% difference between the
means of experimental and control groups with a power of 80%
and P-value of 0.01. Gain-of-function and loss-of-function experi-
ments were also performed to manipulate miR-210 and ISCU1/2
expression in the pulmonary vasculature of mice, followed by
molecular and physiologic analyses relevant to Fe-S-dependent
functions. The number of animals in each group was calculated to
measure a 25% difference between the means of experimental and
control groups with a power of 80% and P-value of 0.01. Animal
treatments were conducted in a controlled and non-blinded
manner. Finally, a rare ISCU mut/mut individual was recruited for
advanced cardiopulmonary exercise testing in order to determine
undiagnosed pulmonary vascular disease. EPR experiments on
human tissue, in situ expression/histologic analyses of both mouse
and human tissue, and respiratory complex activity and pulmo-
nary vascular hemodynamics in mice were performed in a blinded
fashion.
Ethical approval and human study participants
All experimental procedures involving the use of human tissue
and plasma were approved by the Partners Healthcare, Boston
Children’s Hospital, and University of California, Los Angeles
Institutional Review Boards, and the New England Organ Bank.
Ethical approval for this study conformed to the standards of the
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report. Informed consent from the ISCU mut/
mut individual was obtained for advanced cardiopulmonary exer-
cise testing. For formalin-fixed paraffin-embedded lung samples,
human PH specimens were collected from unused or discarded
surgical samples; non-diseased human lung specimens from the
New England Organ Bank have been described (Kajstura et al,
2011). For fresh-frozen lung tissue, human PH specimens were
collected from patients undergoing lung transplantation; non-PH
specimens were collected from lungs that were deemed unsuitable
as donor organs for unrelated reasons. For plasma harvest and
analysis, human subjects were chosen with clinically significant
dyspnea and undergoing right heart catheterization. Subjects were
stratified by the presence or absence of clinical PH, as defined by
elevated mean pulmonary arterial pressure > 25 mmHg (mean
PAP).
Mouse models
The Harvard Center for Comparative Medicine approved the use of
animals in these experiments; such housing, husbandry, and use
adhered to the NIH Guide for the Care and Use of Laboratory
Animals. Their descriptions are detailed in Supplementary Materials
and Methods.
The paper explained
Problem
Iron–sulfur (Fe-S) clusters are essential bioinorganic factors that facili-
tate mitochondrial metabolism. However, exceedingly little is known
about the regulation and function of Fe-S clusters in chronic acquired
human diseases. Pulmonary hypertension (PH) is a deadly and
increasingly prevalent vascular disease characterized by metabolic
dysfunction where Fe-S biology may figure prominently.
Results
We present evidence in mice and humans whereby the hypoxia-
inducible microRNA-210 down-regulates its target ISCU1/2 in order to
regulate the pulmonary vascular and endothelial expression of Fe-S
clusters both through acquired injury (e.g. hypoxia) and genetic muta-
tions. Furthermore, using genetic and pharmacologic methods to
perform gain-of-function and loss-of-function analyses in the rodent
pulmonary vasculature in vivo coupled with the first-known observa-
tion of pulmonary vasculopathy in a human harboring a loss-of-
function mutation of ISCU, we define the microRNA-210-ISCU1/2 axis
as an overarching upstream pathogenic mechanism, central to the
vascular and endothelial metabolic alterations that promote PH.
Impact
The elucidation of Fe-S deficiency as an upstream metabolic origin in
PH carries broad translational implications for identifying currently
undiagnosed individuals at risk for PH and for more effective thera-
peutic targeting. Furthermore, as much remains unknown about the
regulation and function of Fe-S clusters in chronic acquired human
diseases, these results could define an entirely novel disease origin
applicable to conditions other than PH that share similar hypoxic–
ischemic and metabolic pathogenesis.
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Advanced cardiopulmonary exercise testing
An individual with known homozygous intronic mutations in ISCU
(ISCU mut/mut) (Sanaker et al, 2010) was referred for a clinically
indicated advanced cardiopulmonary exercise test (CPET), stem-
ming from severe exercise intolerance and dyspnea. Advanced CPET
was performed as described in detail (Tolle et al, 2008b) and in
Supplementary Materials and Methods.
Statistics
Cell culture experiments were performed at least three times and at
least in triplicate for each replicate. The number of animals in each
group was calculated to measure at least a 20% difference between
the means of experimental and control groups with a power of 80%
and standard deviation of 10%. Randomization of animals was not
necessary for adequate analysis. The number of unique patient
samples for this study was determined primarily by clinical avail-
ability. In situ expression/histologic analyses of both rodent and
human tissue and pulmonary vascular hemodynamics in mice and
rats were performed in a blinded fashion. Immunoblot images are
representative of experiments that have been repeated at least three
times. Micrographs are representative of experiments in each rele-
vant cohort. Numerical quantifications represent mean  standard
error of the mean for three or more independent experiments.
Images are representative of experiments that were repeated at least
three times. In appropriately powered datasets, statistical tests were
selected based on the number of experimental groups and nature of
its variables. Frequency distribution histogram analysis was
assessed for normal distribution. Range and standard deviation were
used as indices of variation within each data group and were used
for comparison of variance across statistically comparable groups.
Paired samples were compared by a two-tailed Student’s t-test.
Comparison of multiple samples was performed by ANOVA
followed by Student–Newman–Keuls post hoc testing. A P < 0.05
was considered significant.
Additional information
See Supplementary Materials and Methods regarding plasmids,
mouse models, and protocols of cell culture, transfection, immuno-
blotting, lentivirus production, ELISA, RNA extraction and analysis,
echocardiography, tissue harvest and in situ staining, respiratory
Complex I activity assays, EPR spectroscopy, PECAM+ cell separa-
tion and flow cytometry, delivery of miRNA mimic oligonucleotides,
miRNA inhibitors, and siRNAs to the pulmonary vasculature of
mice, and advanced CPET, as we have previously described (Chan
et al, 2009; Parikh et al, 2012; Bertero et al, 2014).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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